Chairs D. Papadatos-Pastos (UK), G. Tsakonas (SWE)
08.30-08.50 Genomic profile of SCLC and treatment of LS-SCLC F. I. Dimitrakopoulos (GR)
08.50-09.10 Novel therapeutic advances in ES-SCLC I. Korantzis (GR)
09.10-09.20 Comments/Discussion
Chairs P. Shaw (UK), D. Papadatos-Pastos (UK), N. Panagiotopoulos (UK)
09.20-09.40 HIT meso P. Shaw (UK)
09.40-10.00 Case Mesothelioma S. Zemerly (UK)
Chairs: F. Dimitrakopoulos (GR), I.Metaxas (SUI)
11.00-11.20 The future of the treatment of ALK+ NSCLC: An update D. Thomaidou (GR)
11.20-11.40 EGFR mutant NSCLC: Overcoming the resistance to 3rd generation EGFR TKIs and new therapeutic options G. Tsakonas (SWE)
11.40-12.10 The importance of co-mutations in NSCLC N. Karachaliou (DE)
12.10-12.30 Comments/Discussion
Chairs A. Kotsakis (GR), F. Dimitrakopoulos (GR)
10.30-10.50 Τhe treatment of ALK+ NSCLC: An update P. Christopoulos (DE)
10.50-11.10 EGFR mutant NSCLC: Intensifying First-Line Treatment in EGFR-Driven Lung Cancer D. Papadatos-Pastos (UK)
11.10-11.30 The treatment of EGFR mutant NSCLC beyond the first line G. Tsakonas (SWE)
11.30-11.40 Comments/Discussion
Chairs A. Boutis (GR), G. Fotopoulos (CY)
11.40-12.00 Case 1 (KRAS G12C) G. Oikonomopoulos (GR)
12.00-12.20 Case 2 (ROS1-repotrectinib) E. Fergadis (GR)
12.20-12.40 Case 3 (HER2) G. Fotopoulos (CY)
12.40-13.00 Case 4 (c-MET) N. Asimakopoulou (GR)
13.00-13.10 Discussion: O. Fiste (GR), P. Christopoulos (DE), G. Maravelis (GR), P. Constantoulakis (GR)
Chair V. Georgoulias (GR), P. Constantoulakis (GR)
13.10-13.30 ctDNA for the Detection of Minimal Residual Disease (MRD) S. Giannoulakis (GR)
13.30-13.50 The liquid biopsy as a tool for early cancer detection A. Markou (GR)
13.50-14.10 Homologous Recombination Deficiency: a more universal therapeutic target in cancer cells? A. Klinakis (GR)
14.10-14.20 Comments/Discussion
Chairs Ph. Koinis (GR), V. Georgoulias (GR)
15.20-15.40 The new landscape of ADCs in NSCLC A. Grivas (GR)
15.40-16.00 Lung Cancer Pipeline; Future breakthroughs under development Ch. Michailidi (GR)
16.00-16.10 Discussion
Chairs F.I. Dimitrakopoulos (GR), D. Papadatos-Pastos (UK)
16.10-16.30 The need for a Thoracic research network V. Georgoulias (GR) F.I. Dimitrakopoulos (GR)
16.30-16.50 Clinical significance of Patras Immunotherapy Score (PIOS) & PDCD1 gene SNPs in NSCLC patients F.I. Dimitrakopoulos (GR)
16.50-17.10 HRD and immunotherapy in early early NSCLC (Pathology and Molecular Biology projects) V. Anastasopoulou (GR) I. Pateras (GR), A. Klinakis (GR)
17.10-17.40 Holistic liquid biopsy approach in patients with NSCLC A. Markou (GR), G. Kallergi (GR) A. Xagara / A. Kotsaki’s group (GR)
Chairs Κ. Tsapakidis (GR), Ch. Panopoulos (GR)
18.20-18.40 Adjuvant & peri-operative immunotherapy in operable NSCLC: The Future G. Evangelou (GR)
18.40-19.00 Radio-chemotherapy in non-operable locally advanced NSCLC A.-M. Shiarli (CY)
19.00-19.15 Comments/Discussion
Chairs P. Christopoulos (DE), E. Fergadis (GR)
08.30-08.50 Treatment of ALK early-stage NSCLC: A changed landscape A. Koulouris (SWE)
08.50-09.10 Treatment of EGFR mutant early-stage NSCLC Th. Tegos (GR)
09.10-09.30 The future of oncogene-driven stage I - IIIC NSCLC with TKIs beyond EGFR & ALK G. Fotopoulos (CY)
09.30-09.40 Comments / Discussion
Chairs P. Christopoulos (DE), E. Fergadis (GR)
Setting the survival standards in NSCLC Ο. Fiste (GR)
Sponsored by MSD
Chairs Α. Tsaroucha (GR), Ι. Georgakopoulos (GR)
10.10-10.30 Interventional Pulmonology management of malignant airway obstruction: Palliative or Therapeutic approach? Gr. Stratakos (GR)
10.30-10.50 The role of interventional radiologist in thoracic oncology A. Diamantopoulos (UK)
10.50-11.10 Pain management in cancer patients Z. Κοntouli (GR)
11.10-11.20 Discussion
Chairs P. Christopoulos (DE), F.I. Dimitrakopoulos (GR)
11.50-12.20 Accurate testing in NSCLC correlates with survival? A real word case for EGFR at Evangelismos Hospital Th.Tegos (GR)
12.20-12.50 Modulation of the Microbiome to improve Immunotherapy efficacy H. Charalambous (CY)
12.50-13.20 Challenges for the thoracic surgeon In the era of neoadjuvant treatment N. Panagiotopoulos (UK)
13.20-14.30 Summary of exchange sessions - general discussion / comments
Chairs D. Papadatos-Pastos (UK), N. Panagiotopoulous (UK)
16.00-16.20 Case 1 Adjuvant immunotherapy I. Vathiotis (GR)
16.20-16.40 Case 2 Peri-operative S. Arora (UK)
16.40-17.00 Case 3 Lung cancer and pseudoprogression in immunotherapy G. Christodoulopoulos (GR) / K.Tsapakidis (GR)
Board A. Charpidou (GR), E. Zervas (GR), K.Tsapakidis (GR), K. Papagiannopoulos (UK), A. Dimopoulos (GR)
Chairs A. Kotsakis (GR), P. Savvides (US)
17.00-17.20 Immunotherapy: State of the art in metastatic lung cancer in the 1st line setting E. Fergadis (GR)
17.20-17.40 Therapeutic options after immunotherapy failure Ch. Charalambous (CY)
17.40-18.00 IO in metastatic frail lung cancer patients D. Papadatos-Pastos (UK)
18.00-18.10 Comments / Discussion
Chairs Ch. Charalambous (CY), D. Papadatos-Pastos (UK)
18.30-19.00 Cellular therapies in lung cancer M. Al Bakir (UK)
19.00-19.30 Vaccines in lung cancer V. Karantza (US)




















